Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis

Bibliography

• Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility–associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011;32(4):387-90
   PubMed Web of Science ®Google Scholar
• Tillotson GS, Tillotson J. Clostridium difficile--a moving target. F1000 Med Rep 2011;3:6
   PubMedGoogle Scholar
• Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Cmaj 2004;171(5):466-72
   PubMed Web of Science ®Google Scholar
• Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP statistical brief no. 124. US Department of Health and Human Services, Agency for Healthcare Research and Quality; Rockville, MD: 2011
   Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Eng J Med 2008;359(18):1932-40
   PubMed Web of Science ®Google Scholar
• O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterol 2009;136(6):1913
   PubMedGoogle Scholar
• Popoff MR, Rubin E, Gill D, et al. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988;56(9):2299-306
   PubMedGoogle Scholar
• Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Eng J Med 2005;353(23):2442-9
   PubMed Web of Science ®Google Scholar
• Sirard S, Valiquette L, Fortier LC. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 2011;49(12):4040-6
   PubMed Web of Science ®Google Scholar
• Merrigan M, Venugopal A, Mallozzi M, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010;192(19):4904-11
   PubMed Web of Science ®Google Scholar
• Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010;10(6):395-404
   PubMed Web of Science ®Google Scholar
• The U.S. Food and Drug Administration (FDA). Anti-Infective Drug Advisory Committee Meeting Briefing Document April 5, 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM249354.pdf
   Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi K, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec. Canada. Clin Infect Dis 2005;40(11):1591-7
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31
   PubMed Web of Science ®Google Scholar
• Musgrave CR, Bookstaver PB, Sutton SS, et al. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011;15(7):e438-48
   PubMed Web of Science ®Google Scholar
• Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010;8(5):555-64
   PubMed Web of Science ®Google Scholar
• Baines SD, O’Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62(5):1046-52
   PubMed Web of Science ®Google Scholar
• Spigaglia P, Barbanti F, Mastrantonio P, et al. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011;66(10):2227-34
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407-15
   PubMed Web of Science ®Google Scholar
• Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012;307(18):1959-69
   PubMed Web of Science ®Google Scholar
• Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol 2013;6(1):53-68
   PubMed Web of Science ®Google Scholar
• McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15(6):274-80
   PubMed Web of Science ®Google Scholar
• D'Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324(7350):1361
   PubMed Web of Science ®Google Scholar
• Johnson S, Maziade P-J, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? International J Infect Dis 2012;16(11):e786-e92
   PubMed Web of Science ®Google Scholar
• Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of lactobacillus acidophilus cl1285 and lactobacillus casei LBC80R for antibiotic-associated diarrhea and clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105(7):1636-41
   PubMed Web of Science ®Google Scholar
• Johnson S, Homann SR, Bettin KM, et al. Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole: a Randomized, Placebo-controlled Trial. Ann Intern Med 1992;117(4):297-302
   PubMed Web of Science ®Google Scholar
• Brown KA, Khanafer N, Daneman N, et al. Antibiotics and the risk of community-associated Clostridium difficile infection (CDI): a meta-analysis. Antimicrob Agents Chemother 2013; [Epub ahead of print]
   Google Scholar
• Erb W, Zhu J. From natural product to marketed drug: the tiacumicin odyssey. Nat Prod Rep 2013;30(1):161-74
   PubMedGoogle Scholar
• Srivastava A, Talaue M, Liu S, et al. New target for inhibition of bacterial RNA polymerase: ‘switch region’. Curr Opin Microbiol 2011;14(5):532-43
   PubMedGoogle Scholar
• Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):261-3
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48(12):4898-902
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Ross JE, Putnam SD, et al. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 2010;54(5):2273-5
   PubMedGoogle Scholar
• Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010;156(Pt 11):3354-9
   PubMed Web of Science ®Google Scholar
• Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 2011;9(7):767-77
   PubMed Web of Science ®Google Scholar
• Miller M. Fidaxomicin (OPT-80) for the treatment of clostridium difficile infection. Expert Opin Pharmacother 2010;11(9):1569-78
   PubMed Web of Science ®Google Scholar
• Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 2012;55(Suppl 2):S127-S31
   PubMedGoogle Scholar
• Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012;55(suppl 2):S143-S48
   PubMedGoogle Scholar
• Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-8
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12(4):281-9
   PubMed Web of Science ®Google Scholar
• The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients. Washington University School of Medicine. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01552668?term = fidaxomicin&rank = 1
   Google Scholar
• Safety and efficacy of fidaxomicin versus placebo for prophylaxis against clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation (DEFLECT-1). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01691248?term = fidaxomicin&rank=3
   Google Scholar
• Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52(11):4163-5
   PubMed Web of Science ®Google Scholar
• Mullane KM, Miller MA, Weiss K, et al. Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections. Clin Infect Dis 2011;53(5):440-7
   PubMed Web of Science ®Google Scholar
• Linsky A, Gupta K, Hermos JA. Fidaxomicin for Clostridium difficile infection. N Engl J Med 2011;364(19):1875; author reply 75-6
   PubMedGoogle Scholar